Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease

Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and haemostasis 2007-02, Vol.5 (2), p.282-288
Hauptverfasser: BARONCIANI, L., FEDERICI, A. B., COZZI, G., CANCIANI, M. T., MANNUCCI, P. M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 288
container_issue 2
container_start_page 282
container_title Journal of thrombosis and haemostasis
container_volume 5
creator BARONCIANI, L.
FEDERICI, A. B.
COZZI, G.
CANCIANI, M. T.
MANNUCCI, P. M.
description Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.
doi_str_mv 10.1111/j.1538-7836.2007.02349.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68971841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68971841</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</originalsourceid><addsrcrecordid>eNqNUcFu1DAQtRCIlsIvoDkhOGyw42TtHDi0FaWgSlwKPVqOMyZeJXGws90u_8d_4WQXkDjhi9943nsz8iMEGM1YOm83GSu5XAnJ11lOqchozosqe3hETv80Hv_GFecn5FmMG0pZVeb0KTlhgpVlVYhT8vPCedNi74zuwLQ6aDNhcD_05PwA3oKGgMb3tRv0MMF9erxzXYd10EMDNrF9gNdf767ewM5NLRyo2MC0HxHyC5hpC2bQoEUzRXADTC1CEsE3HHCpdx7GNBOH1F-M9NHhHMYWB78UaZ1_FmhcRB3xOXlidRfxxfE-I1-u3t9eXq9uPn_4eHl-szJ8LapVTQvOTclMURQls03OcyoTKNJX5FY0tDJWI7eyriQvqdC8trWsGG0amwvO-Rl5dfAdg_--xTip3kWDXacH9Nuo1rISTBYsEeWBaIKPMaBVY3C9DnvFqJojVBs1p6PmpNQcoVoiVA9J-vI4Y1v32PwVHjNLhHcHws51uP9vY_Xp9npG_BeMKqwE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68971841</pqid></control><display><type>article</type><title>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>BARONCIANI, L. ; FEDERICI, A. B. ; COZZI, G. ; CANCIANI, M. T. ; MANNUCCI, P. M.</creator><creatorcontrib>BARONCIANI, L. ; FEDERICI, A. B. ; COZZI, G. ; CANCIANI, M. T. ; MANNUCCI, P. M.</creatorcontrib><description>Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2007.02349.x</identifier><identifier>PMID: 17155947</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Collagen - metabolism ; Dimerization ; expression study ; Family Health ; Humans ; Male ; Middle Aged ; Mutation, Missense ; Pedigree ; Platelet Glycoprotein GPIb-IX Complex - metabolism ; Protein Binding ; Recombinant Proteins - genetics ; Siblings ; type 1 ; type 2A ; type 2B ; von Willebrand disease ; von Willebrand Diseases - classification ; von Willebrand Diseases - diagnosis ; von Willebrand Diseases - genetics ; von Willebrand Factor - genetics</subject><ispartof>Journal of thrombosis and haemostasis, 2007-02, Vol.5 (2), p.282-288</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</citedby><cites>FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17155947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARONCIANI, L.</creatorcontrib><creatorcontrib>FEDERICI, A. B.</creatorcontrib><creatorcontrib>COZZI, G.</creatorcontrib><creatorcontrib>CANCIANI, M. T.</creatorcontrib><creatorcontrib>MANNUCCI, P. M.</creatorcontrib><title>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.</description><subject>Collagen - metabolism</subject><subject>Dimerization</subject><subject>expression study</subject><subject>Family Health</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation, Missense</subject><subject>Pedigree</subject><subject>Platelet Glycoprotein GPIb-IX Complex - metabolism</subject><subject>Protein Binding</subject><subject>Recombinant Proteins - genetics</subject><subject>Siblings</subject><subject>type 1</subject><subject>type 2A</subject><subject>type 2B</subject><subject>von Willebrand disease</subject><subject>von Willebrand Diseases - classification</subject><subject>von Willebrand Diseases - diagnosis</subject><subject>von Willebrand Diseases - genetics</subject><subject>von Willebrand Factor - genetics</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUcFu1DAQtRCIlsIvoDkhOGyw42TtHDi0FaWgSlwKPVqOMyZeJXGws90u_8d_4WQXkDjhi9943nsz8iMEGM1YOm83GSu5XAnJ11lOqchozosqe3hETv80Hv_GFecn5FmMG0pZVeb0KTlhgpVlVYhT8vPCedNi74zuwLQ6aDNhcD_05PwA3oKGgMb3tRv0MMF9erxzXYd10EMDNrF9gNdf767ewM5NLRyo2MC0HxHyC5hpC2bQoEUzRXADTC1CEsE3HHCpdx7GNBOH1F-M9NHhHMYWB78UaZ1_FmhcRB3xOXlidRfxxfE-I1-u3t9eXq9uPn_4eHl-szJ8LapVTQvOTclMURQls03OcyoTKNJX5FY0tDJWI7eyriQvqdC8trWsGG0amwvO-Rl5dfAdg_--xTip3kWDXacH9Nuo1rISTBYsEeWBaIKPMaBVY3C9DnvFqJojVBs1p6PmpNQcoVoiVA9J-vI4Y1v32PwVHjNLhHcHws51uP9vY_Xp9npG_BeMKqwE</recordid><startdate>200702</startdate><enddate>200702</enddate><creator>BARONCIANI, L.</creator><creator>FEDERICI, A. B.</creator><creator>COZZI, G.</creator><creator>CANCIANI, M. T.</creator><creator>MANNUCCI, P. M.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200702</creationdate><title>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</title><author>BARONCIANI, L. ; FEDERICI, A. B. ; COZZI, G. ; CANCIANI, M. T. ; MANNUCCI, P. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3679-b0433c51c44451fd2320851f49472f7d09cfae3f8b983507a3bfb8910ddf27333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Collagen - metabolism</topic><topic>Dimerization</topic><topic>expression study</topic><topic>Family Health</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation, Missense</topic><topic>Pedigree</topic><topic>Platelet Glycoprotein GPIb-IX Complex - metabolism</topic><topic>Protein Binding</topic><topic>Recombinant Proteins - genetics</topic><topic>Siblings</topic><topic>type 1</topic><topic>type 2A</topic><topic>type 2B</topic><topic>von Willebrand disease</topic><topic>von Willebrand Diseases - classification</topic><topic>von Willebrand Diseases - diagnosis</topic><topic>von Willebrand Diseases - genetics</topic><topic>von Willebrand Factor - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARONCIANI, L.</creatorcontrib><creatorcontrib>FEDERICI, A. B.</creatorcontrib><creatorcontrib>COZZI, G.</creatorcontrib><creatorcontrib>CANCIANI, M. T.</creatorcontrib><creatorcontrib>MANNUCCI, P. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARONCIANI, L.</au><au>FEDERICI, A. B.</au><au>COZZI, G.</au><au>CANCIANI, M. T.</au><au>MANNUCCI, P. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2007-02</date><risdate>2007</risdate><volume>5</volume><issue>2</issue><spage>282</spage><epage>288</epage><pages>282-288</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Background: In a patient previously diagnosed with type 2A von Willebrand disease (VWD) [absence of high and intermediate molecular weight von Willebrand factor (VWF) multimers and markedly reduced ristocetin‐induced platelet aggregation (RIPA)], an infusion test of desmopressin was followed by mild thrombocytopenia. This led to further laboratory investigations of his affected brother and of family members, who showed different phenotypic patterns compatible with type 1, 2A, 2B and an uncertain classification of VWD. The two brothers were compound heterozygotes (C275R/P1337L), whereas the others members of the family were heterozygous for C275R (a novel mutation in the D1 domain) or P1337L (a type 2B mutation in the A1 domain). Objective and methods: To evaluate the role of the combined effect of the two mutations in the two brothers, C275R and P1337L recombinant (r) VWFs were transiently expressed in COS‐7 cells. Results: Recombinant VWF levels secreted in cell media were similar for wild‐type (WT), P1337L and hybrid P1337L/WT rVWFs, reduced for hybrids C275R/P1337L and C275R/WT rVWFs, and strongly reduced for C275R rVWF. All rVWFs had a full set of multimers except C275R rVWF, which had only dimers. P1337L rVWF and C275R/P1337L rVWF showed the highest degree of binding to glycoprotein (GP) Ibα and the lowest to collagen, followed by P1337L/WT rVWF (with an intermediate level of binding to both ligands), and by WT rVWF with the lowest level of binding to GPIbα and the highest to collagen. Conclusion: These results suggest that the two compound heterozygous patients have a circulating VWF mainly mutated in the A1 domain (P1337L). This peculiar type 2B VWF variant showed a remarkably high affinity for the GPIbα platelet receptor, leading to the loss of high and intermediate molecular weight multimers and hence to decreased RIPA, as in type 2A VWD.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17155947</pmid><doi>10.1111/j.1538-7836.2007.02349.x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1538-7933
ispartof Journal of thrombosis and haemostasis, 2007-02, Vol.5 (2), p.282-288
issn 1538-7933
1538-7836
1538-7836
language eng
recordid cdi_proquest_miscellaneous_68971841
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Collagen - metabolism
Dimerization
expression study
Family Health
Humans
Male
Middle Aged
Mutation, Missense
Pedigree
Platelet Glycoprotein GPIb-IX Complex - metabolism
Protein Binding
Recombinant Proteins - genetics
Siblings
type 1
type 2A
type 2B
von Willebrand disease
von Willebrand Diseases - classification
von Willebrand Diseases - diagnosis
von Willebrand Diseases - genetics
von Willebrand Factor - genetics
title Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T22%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biochemical%20characterization%20of%20a%20recombinant%20von%20Willebrand%20factor%20(VWF)%20with%20combined%20type%202B%20and%20type%201%20defects%20in%20the%20VWF%20gene%20in%20two%20patients%20with%20a%20type%202A%20phenotype%20of%20von%20Willebrand%20disease&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=BARONCIANI,%20L.&rft.date=2007-02&rft.volume=5&rft.issue=2&rft.spage=282&rft.epage=288&rft.pages=282-288&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2007.02349.x&rft_dat=%3Cproquest_cross%3E68971841%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68971841&rft_id=info:pmid/17155947&rfr_iscdi=true